



## Pharmascience announces \$120 million expansion of Candiatic injectable manufacturing facilities

CANDIAC, QC, Pharmascience Inc. (Pharmascience) is pleased to announce a major expansion of its sterile injectable manufacturing facility in Candiatic, Québec.

As the largest Canadian-owned pharmaceutical company, Pharmascience is dedicated to building on its 40 years of expertise in pharmaceutical manufacturing by investing in growth in Québec. This major expansion project will allow Pharmascience to triple its injectable manufacturing capacity.

With the new plant expansion coming online in 2026, this project will:

- Build on our strengths in R&D to attract more Contract Development and Manufacturing (CMO and CDMO) projects
- Improve Canada's domestic biomanufacturing capabilities and ability to meet our pharmaceutical supply chain needs
- Increase manufacturing efficiency and result in faster response times to product shortages or urgent health challenges
- Fully implant Pharmascience as the Canadian leader in specialized, ***cytotoxic and high-potency injectable*** pharmaceutical manufacturing

This project will triple Pharmascience's current injectable manufacturing capacity from its 2021 level, with the addition of new, more efficient equipment. The new facility comprises approximately 26,000 square feet of new manufacturing space and equipment, and a retrofit of approximately 7,500 square feet to Pharmascience's existing manufacturing facilities.

Valued at a total of \$120 million, this project is supported by the Government of Canada's Strategic Innovation Fund at \$29.77 million and by the Government of Québec through investment Québec at \$24.75 million.

50 new high-skilled advanced manufacturing jobs will be created as a result of the project, with the project supporting an additional 300 jobs.

### ABOUT PHARMASCIENCE INC.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With 1,500 employees proudly headquartered in Montreal, Pharmascience Inc. is a full-service CDMO and privately-owned pharmaceutical company with strong roots in Canada and a growing global reach, with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research and Development (R&D) investors in 2022, with \$40-50 million in annual investment, Pharmascience Inc. is among the largest drug manufacturers in Canada.